Drug Profile
R 801
Alternative Names: R-801Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Radikal Therapeutics
- Developer Radikal Therapeutics; Tisbury Pharmaceuticals
- Class Eye disorder therapies; Small molecules; Urologics
- Mechanism of Action KATP channel stimulants; Superoxide dismutase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bronchopulmonary dysplasia; Kidney disorders; Open-angle glaucoma; Reperfusion injury
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Open-angle-glaucoma in USA (Intraocular, Injection)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Kidney-disorders in USA (IV)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Reperfusion-injury in USA (IV)